Clinical usefulness of serum tartrate-resistant fluoride-sensitive acid phosphatase activity in evaluating bone turnover.
This study was carried out to evaluate the clinical validity and usefulness of serum tartrate-resistant fluoride-sensitive acid phosphatase (TrFsACP) activity using 2,6-dichloro-4-acetylphenyl phosphate as substrate at pH 6.2 in metabolic bone diseases. The mean Z-scores of TrFsACP activity in patients on hemodialysis were higher than in healthy subjects (male: 2.04+/-1.98, n = 49, P < .05; female: 1.49+/-2.43, n = 39, P < .05) and increased with duration of hemodialysis (r = .516, P < .01). Bone alkaline phosphatase also was found to be significantly higher in hemodialysis patients (male: 0.93+/-1.49, P < .05; female: 1.66+/-2.42, P < .05) compared with normal subjects: but had lower correlation with duration of hemodialysis than TrFsACP (r = .277, P < .05). Ulcerative colitis (1.37+/-2.21, n = 15) in males showed a significantly higher Z-score of TrFsACP compared with control subjects (P < .05). The relationship of TrFsACP activity and ultrasound findings (stiffness; speed of sound [SOS]; broadband ultra sound attenuation [BUA]) in healthy women aged 30-75 years (n = 95) were inversely and significantly correlated with stiffness (r = -.465, P < .01 ), SOS (r = -.484, P < .01), and BUA (r = -.366, P < .01), but were age dependent. TrFsACP activity significantly correlated with stiffness (r = -.521, P < .05) and SOS (r = -.527, P < .05) only in the age group of 46-55 years. BUA (r = -.313, P > .05) did not correlate significantly in any subject in the present study. We conclude that serum TrFsACP activity is useful in the diagnosis and monitoring of bone turnover.
Nakanishi
M
M
Department of Clinical Pathology, Hyogo College of Medicine, Nishinomiya, Japan.
Yoh
K
K
Uchida
K
K
Maruo
S
S
Rai
S K
SK
Matsuoka
A
A
D000135:Acid Phosphatase / Q000097:blood* / Q000187:drug effects; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D016723:Bone Remodeling; D001842:Bone and Bones / Q000000981:diagnostic imaging* / Q000378:metabolism*; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000378:metabolism; D005260:Female; D005459:Fluorides / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010013:Osteogenesis Imperfecta / Q000378:metabolism; D010024:Osteoporosis / Q000378:metabolism; D011237:Predictive Value of Tests; D012016:Reference Values; D006435:Renal Dialysis; D013644:Tartrates / Q000494:pharmacology; D014463:Ultrasonography
D015415:Biomarkers; D013644:Tartrates; D000135:Acid Phosphatase; D005459:Fluorides; C029768:tartaric acid